Rein Therapeutics, Inc. Payments to Acquire Debt Securities, Available-for-sale
Rein Therapeutics, Inc. (RNTX) reported Payments to Acquire Debt Securities, Available-for-sale of $21.85 million for the 12-month period ending 2022-12-31, per its 10-K filed 2024-04-15.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2024-04-15
- Rein Therapeutics, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2022-12-31 was $1.94M, a 29.50% decline year-over-year.
- Rein Therapeutics, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2022-09-30 was $7.81M, a 60.38% decline year-over-year.
- Rein Therapeutics, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2022-06-30 was $7.39M, a 26.00% decline year-over-year.
- Rein Therapeutics, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2022-03-31 was $4.71M, a 88.54% decline year-over-year.
- Rein Therapeutics, Inc. payments to acquire debt securities, available-for-sale for fiscal 2022 was $21.85M, a 70.30% decline from fiscal 2021.
- Rein Therapeutics, Inc. payments to acquire debt securities, available-for-sale for fiscal 2021 was $73.58M, a 633.28% increase from fiscal 2020.
- Rein Therapeutics, Inc. payments to acquire debt securities, available-for-sale for fiscal 2020 was $10.03M, a 63.16% decline from fiscal 2019.
- Rein Therapeutics, Inc. payments to acquire debt securities, available-for-sale for fiscal 2019 was $27.24M, a 12.69% decline from fiscal 2018.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2022-12-31 | $1.94M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-15 | $9.75M derived: sum of 2 quarters · filed 2024-04-15 | $17.14M derived: sum of 3 quarters · filed 2024-04-15 | $21.85M 10-K · filed 2024-04-15 |
| 2022-09-30 | $7.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-13 | $15.20M derived: sum of 2 quarters · filed 2023-10-13 | $19.91M 10-Q · filed 2023-10-13 | $22.66M derived: sum of 4 quarters · filed 2023-10-13 |
| 2022-06-30 | $7.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | $12.10M 10-Q · filed 2023-08-11 | $14.85M derived: sum of 3 quarters · filed 2023-08-11 | $34.57M derived: sum of 4 quarters · filed 2023-08-11 |
| 2022-03-31 | $4.71M 10-Q · filed 2023-05-08 | $7.46M derived: sum of 2 quarters · filed 2023-05-08 | $27.18M derived: sum of 3 quarters · filed 2023-05-08 | $37.16M derived: sum of 4 quarters · filed 2023-05-08 |
| 2021-12-31 | $2.75M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-20 | $22.47M derived: sum of 2 quarters · filed 2023-03-20 | $32.45M derived: sum of 3 quarters · filed 2023-03-20 | $73.58M 10-K · filed 2023-03-20 |
| 2021-09-30 | $19.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | $29.70M derived: sum of 2 quarters · filed 2022-11-01 | $70.83M 10-Q · filed 2022-11-01 | $72.83M derived: sum of 4 quarters · filed 2022-11-01 |
| 2021-06-30 | $9.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $51.10M 10-Q · filed 2022-08-15 | $53.10M derived: sum of 3 quarters · filed 2022-08-15 | $59.38M derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | $41.12M 10-Q · filed 2022-05-05 | $43.12M derived: sum of 2 quarters · filed 2022-05-05 | $49.40M derived: sum of 3 quarters · filed 2022-05-05 | |
| 2020-12-31 | $2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $8.28M derived: sum of 2 quarters · filed 2022-03-28 | $10.03M 10-K · filed 2022-03-28 | |
| 2020-09-30 | $6.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $8.04M 10-Q · filed 2021-11-12 | ||
| 2020-06-30 | $1.76M 10-Q · filed 2021-08-11 | |||
| 2019-12-31 | $2.73M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-24 | $5.95M derived: sum of 2 quarters · filed 2021-03-24 | $27.24M 10-K · filed 2021-03-24 | |
| 2019-09-30 | $3.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $24.51M 10-Q · filed 2020-11-12 | ||
| 2019-06-30 | $21.28M 10-Q · filed 2020-08-05 | |||
| 2018-12-31 | $4.96M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-30 | $10.43M derived: sum of 2 quarters · filed 2020-03-30 | $23.65M derived: sum of 3 quarters · filed 2020-03-30 | $31.19M 10-K · filed 2020-03-30 |
| 2018-09-30 | $5.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $18.68M derived: sum of 2 quarters · filed 2019-11-07 | $26.23M 10-Q · filed 2019-11-07 | $45.16M derived: sum of 4 quarters · filed 2019-11-07 |
| 2018-06-30 | $13.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $20.76M 10-Q · filed 2019-08-06 | $39.69M derived: sum of 3 quarters · filed 2019-08-06 | $83.07M derived: sum of 4 quarters · filed 2019-08-06 |
| 2018-03-31 | $7.55M 10-Q · filed 2019-05-08 | $26.47M derived: sum of 2 quarters · filed 2019-05-08 | $69.86M derived: sum of 3 quarters · filed 2019-05-08 | $71.34M derived: sum of 4 quarters · filed 2019-05-08 |
| 2017-12-31 | $18.93M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-29 | $62.31M derived: sum of 2 quarters · filed 2019-03-29 | $63.79M derived: sum of 3 quarters · filed 2019-03-29 | $71.06M 10-K · filed 2019-03-29 |
| 2017-09-30 | $43.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $44.87M derived: sum of 2 quarters · filed 2018-11-07 | $52.13M 10-Q · filed 2018-11-07 | $52.13M derived: sum of 4 quarters · filed 2018-11-07 |
| 2017-06-30 | $1.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $8.75M 10-Q · filed 2018-08-07 | $8.75M derived: sum of 3 quarters · filed 2018-08-07 | $9.49M derived: sum of 4 quarters · filed 2018-08-07 |
| 2017-03-31 | $7.26M 10-Q · filed 2018-05-09 | $7.26M derived: sum of 2 quarters · filed 2018-05-09 | $8.01M derived: sum of 3 quarters · filed 2018-05-09 | |
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-04-02 | $747.00K derived: sum of 2 quarters · filed 2018-04-02 | $12.63M 10-K · filed 2018-04-02 | |
| 2016-09-30 | $747.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $12.63M 10-Q · filed 2017-11-09 | ||
| 2016-06-30 | $11.89M 10-Q · filed 2017-08-10 | |||
| 2015-12-31 | $2.37M 10-K · filed 2018-04-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |